SUI DeSci agents launches a platform to democratize longevity amid DeSci boom

December 31, 2024 06:04 AM PST | By Invezz

SUI DeSci agents launches a platform to democratize longevity amid DeSci boom — Image source: Invezz

BIO protocol’s Binance listing

On December 23, 2024, Binance posted a tweet announcing the launch of BIO Protocol’s launchpool.

Now users can stake their BNB and FDUSD to earn BIO airdrops over 10 days, with a Binance listing of BIO Protocol scheduled for January 3, 2025.

SUI DeSci Agents at the Forefront of DeSci

SUI Desci Agents is a platform for launching DeSci assets, automatically growing their audience with AI agents, and generating liquidity with mechanics inspired by pump.fun. It aims to democratize access to longevity research investments for retail users.

$DESCI offers a variety of features that make the project unique:

Tokenized Compounds: Users can bet on the potential of longevity compounds like Epitalon and Rapamycin (the first compounds to be launched) by reviewing their scientific data and statistics.
Pluggable AI Agents: LLM-trained AI agents are paired with longevity compounds and promote them 24/7 across social platforms, ensuring efficient outreach.
Layer-2 Liquidity Mechanics: Pairing $DESCI tokens with compounds creates a robust liquidity ecosystem tailored for DeSci.
AI-Powered B2C Products: Wellness tools attract millions of health enthusiasts, driving organic growth and supporting the ecosystem.

The number of DeSci supporters keeps growing

The number of DeSci supporters keeps growing and includes prominent web3 leaders and big web2 VC firms:

Vitalik Buterin emphasized the transformative potential of DeSci projects at the recent Devcon event.
Founder of Coinbase, Brian Armstrong, is backing ResearchHub to drive open scientific collaboration.
A16Z led a $5M funding round for AminoChain, a decentralized biosample marketplace.
Pfizer Ventures participated in a $4.1M funding round of VitaDAO, a project focusing on raising funds for research that expands human lifespan.

2025: the year of $DeSci

In November 2024, pump.science launched two tokens, Rifampicin and Urolithin A, which have since attracted attention in the market.

Their market capitalizations reached approximately $125 million and $45 million, respectively, within a few days of their introduction.

The decentralized science (DeSci) sector continues to expand, with SUI DeSci Agents establishing itself as a potential leader.

The project is developing a platform where retail audience can invest in tokenized longevity compounds.

They are also working on AI-powered B2C wellness tools that would help SUI Desci Agents to onboard more users into the ecosystem.

As an interest in decentralized approache to science grows, $DESCI aims to contribute to the evolution of scientific innovation.

About SUI DeSci agents

SUI DeSci Agents is a platform designed to launch DeSci assets, grow their audience with AI agents, and create liquidity through advanced mechanics inspired by pump.fun.

With a hot ticker $DeSci, the project aims to democratize access to longevity research investments, empowering retail audiences to actively participate in scientific advancements.

Contact

Olha Zubarieva
[email protected]

The post SUI DeSci agents launches a platform to democratize longevity amid DeSci boom appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.